Compare
Escalon Medical Corp vs CapsoVision, Inc vs Hyperfine, Inc. vs Nuwellis, Inc.
| Latest fiscal year | Escalon Medical Corp ESMC | CapsoVision, Inc CV | Hyperfine, Inc. HYPR | Nuwellis, Inc. NUWE |
|---|---|---|---|---|
| Year ended | 2025-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $12.05M | $13.55M | $13.56M | $8.27M |
| Revenue growth (YoY) | +0.5% | +15.3% | +5.2% | -5.4% |
| Gross margin | 45.7% (computed) | 52.9% | 49.8% | 62.0% |
| Operating margin | 1.1% | -188.3% | -273.4% | -134.3% |
| Net margin | 0.9% | -186.8% | -262.3% | -211.9% |
| Net income | $105.5K | -$25.32M | -$35.57M | -$17.52M |
| EPS (Diluted) | $0.00 | -$1.03 | -$0.43 | -$25.39 |
| Operating cash flow | $380.7K | -$22.86M | -$27.95M | -$10.81M |
| Free cash flow | $376.8K | -$22.95M | -$29.13M | -$10.90M |
| Cash & equivalents | $545.8K | n/a | $35.09M | $1.08M |
| Total assets | $4.99M | $18.16M | $55.26M | $6.12M |
| Total liabilities | $3.08M | $4.90M | $14.26M | $3.49M |
| Shareholders' equity | $1.92M | $13.26M | $41.01M | $2.62M |
| Return on year-end equity | 5.5% | -190.9% | -86.8% | -667.7% |
| Shares outstanding | 7.42M | 46.87M | n/a | 1.69M |
Revenue, most recent five fiscal years
| Fiscal year | Escalon Medical Corp | CapsoVision, Inc | Hyperfine, Inc. | Nuwellis, Inc. |
|---|---|---|---|---|
| Latest | $12.05M Ended 2025-06-30 | $13.55M Ended 2025-12-31 | $13.56M Ended 2025-12-31 | $8.27M Ended 2025-12-31 |
| 1 year earlier | $11.98M Ended 2024-06-30 | $11.76M Ended 2024-12-31 | $12.89M Ended 2024-12-31 | $8.74M Ended 2024-12-31 |
| 2 years earlier | $12.18M Ended 2023-06-30 | n/a | $11.03M Ended 2023-12-31 | $8.86M Ended 2023-12-31 |
| 3 years earlier | $10.70M Ended 2022-06-30 | n/a | $6.81M Ended 2022-12-31 | $8.54M Ended 2022-12-31 |
| 4 years earlier | $10.47M Ended 2021-06-30 | n/a | $1.50M Ended 2021-12-31 | $7.92M Ended 2021-12-31 |